Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | Q9HBH1 | 1/20 | 0.38 | |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | GOT1 | P17174 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195181 | 0.81 | FAAH (0.39) | MAP4K1FFAR2PDFALDH1A1PTGER4 | |
| SCHEMBL26619952 | 0.81 | FAAH (0.39) | MAP4K1FFAR2PDFALDH1A1PTGER4 | |
| SCHEMBL24433424 | 0.77 | DYRK1A (0.41) | MAP4K1FFAR2PDFALDH1A1HPGD | |
| SCHEMBL30522718 | 0.77 | JAK2 (0.51) | JAK2 | |
| SCHEMBL24433402 | 0.77 | JAK2 (0.51) | JAK2 | |
| SCHEMBL24433497 | 0.77 | CYP1A2 (0.48) | ALDH1A1HPGDLMNAHCRTR1HCRTR2 | |
| SCHEMBL24433518 | 0.76 | NTRK3 (0.51) | MAP4K1ALDH1A1LMNA | |
| SCHEMBL24433504 | 0.74 | MGLL (0.44) | — | |
| SCHEMBL24433420 | 0.74 | MGLL (0.44) | — | |
| SCHEMBL24433506 | 0.74 | MGLL (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4574150-A2 | A MAGL INHIBITOR | H. Lundbeck A/S (DK) | 2025-06-25 | — | — | EP | disclosed |
| EP-4244208-B1 | A MAGL INHIBITOR | H LUNDBECK AS (DK) | 2025-04-02 | — | — | EP | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| CN-116547274-A | MAGL inhibitors | H.隆德贝克有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11434222-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2022-09-06 | — | — | US | disclosed |
| US-20220153721-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | US | disclosed |
| WO-2022101412-A1 | A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | WO | disclosed |
| US-20220153721-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434222-B2 | MAGL inhibitors | MAG, MAGI3, MAGT1 | MAP4K1 510/4885FFAR2 2027/4885PDF 3493/4885 |
| US-20240018120-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | MAP4K1 510/4885FFAR2 2027/4885PDF 3493/4885 |
| US-20220153721-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | MAP4K1 510/4885FFAR2 2027/4885PDF 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.